These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 1382937

  • 1. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Buckley MM, Brogden RN, Barradell LB, Goa KL.
    Drugs; 1992 Sep; 44(3):408-44. PubMed ID: 1382937
    [Abstract] [Full Text] [Related]

  • 2. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
    Balfour JA, Bryson HM, Brogden RN.
    Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
    [Abstract] [Full Text] [Related]

  • 3. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
    Heo YA.
    Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
    [Abstract] [Full Text] [Related]

  • 4. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
    Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM.
    Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
    [Abstract] [Full Text] [Related]

  • 5. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
    Smith JR, Rybak JM, Claeys KC.
    Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
    [Abstract] [Full Text] [Related]

  • 6. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C, Belgian Multicenter Study Group.
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
    Hashira S, Tajima T, Fujii R.
    Jpn J Antibiot; 1989 May; 42(5):1077-86. PubMed ID: 2746857
    [Abstract] [Full Text] [Related]

  • 8. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
    Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A.
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
    [Abstract] [Full Text] [Related]

  • 9. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
    Pastel DA.
    Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT, Kuti JL, Nicolau DP, OPTAMA Program.
    Surg Infect (Larchmt); 2005 Sep; 6(4):419-26. PubMed ID: 16433606
    [Abstract] [Full Text] [Related]

  • 11. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Clissold SP, Todd PA, Campoli-Richards DM.
    Drugs; 1987 Mar; 33(3):183-241. PubMed ID: 3552595
    [Abstract] [Full Text] [Related]

  • 12. Imipenem-cilastatin monotherapy in severe infections accompanying hematological malignancies.
    Urabe A, Takaku F, Mizoguchi H.
    Jpn J Med; 1991 Mar; 30(5):420-3. PubMed ID: 1803041
    [Abstract] [Full Text] [Related]

  • 13. The antimicrobial activity of imipenem/cilastatin and its treatment in critical ill patients with polymicrobial and mixed infection.
    Leu HS, Wu JL.
    Changgeng Yi Xue Za Zhi; 1993 Sep; 16(3):154-63. PubMed ID: 8221288
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ, Botha RF, Poswa X, Senekal M, Badal RE, Grolman DC, Richards GA, Feldman C, Boffard KD, Veller M, Joubert I, Pretorius J.
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [Abstract] [Full Text] [Related]

  • 15. New antibiotics: carbapenems, monobactams and quinolones.
    Amin NM.
    Am Fam Physician; 1988 Oct; 38(4):125-34. PubMed ID: 3051970
    [Abstract] [Full Text] [Related]

  • 16. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R.
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [Abstract] [Full Text] [Related]

  • 17. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections.
    Jia B, Lu P, Huang W, Li C, Huang A, Zhou X, Zhang W, Wu G, Zhang G.
    Chemotherapy; 2010 Apr; 56(4):285-90. PubMed ID: 20714145
    [Abstract] [Full Text] [Related]

  • 18. Imipenem-cilastatin sodium.
    Roach AC.
    Crit Care Nurse; 1989 Mar; 9(3):14-8. PubMed ID: 2582800
    [No Abstract] [Full Text] [Related]

  • 19. Imipenem-cilastatin.
    Dinsmoor MJ.
    Obstet Gynecol Clin North Am; 1992 Sep; 19(3):475-82. PubMed ID: 1436925
    [Abstract] [Full Text] [Related]

  • 20. Imipenem/cilastatin: the first carbapenem antibiotic.
    Lyon JA.
    Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.